Zai Lab gains China approval for first-of-Its-kind cervical cancer therapy

Zai Lab (NASDAQ:ZLAB) announced that China’s National Medical Products Administration has approved its Biologics License Application for TIVDAK, an injectable therapeutic targeting adult patients with recurrent or metastatic cervical cancer.

The regulatory clearance positions the treatment as the first antibody-drug conjugate approved in China for individuals whose disease has progressed during or after standard chemotherapy courses.

The regulatory nod is anchored by clinical readouts from the global, randomized Phase 3 innovaTV 301 trial.

The trial successfully hit its primary objective by demonstrating a statistically significant overall survival benefit for patients treated with TIVDAK when compared directly against traditional chemotherapy regimens.

A localized exploratory subpopulation analyzed within mainland China mirrored the positive global trends, posting a 45% reduction in the risk of death compared to the chemotherapy control group.

Oncology providers note the regulatory milestone addresses a profound clinical deficit in a country where cervical cancer remains a primary cause of cancer-related mortality among women, with roughly 150,000 new diagnoses recorded annually.

Treatment optionality has traditionally narrowed dramatically for advanced patients once first-line chemotherapy fails to halt tumor progression.

The clinical data proved consistent even among patients who had previously undergone immunotherapy, which represents the current second-line standard of care.

Out of the Chinese trial cohort, more than half had been exposed to prior anti-PD(L)1 treatments, yet the survival advantages associated with TIVDAK remained robust regardless of that earlier therapeutic exposure.

No novel or unexpected safety signals emerged from the regional subpopulation analysis, with severe side effects primarily limited to manageable instances of anemia, cough, and malaise.

With China’s approval in hand, Zai Lab joins a network of international regulatory bodies that have validated the treatment, including agencies within the United States, Japan, the European Union, and the United Kingdom, alongside regional clearances in Hong Kong and Macau.